Tag Archives: INT

World shares rebound as investors weigh economy against diplomacy

TOKYO (Reuters) -Global shares bounced back on Friday, with Asian stocks recovering from a three-month low, as investors focused more on optimism about the global economic recovery than rising tensions between the West and China.

FILE PHOTO: A man wearing a protective face mask, following an outbreak of the coronavirus, talks on his mobile phone in front of a screen showing the Nikkei index outside a brokerage in Tokyo, Japan, February 26, 2020. REUTERS/Athit Perawongmetha/File Photo

European stocks look set to open higher, with Euro Stoxx futures rising 0.8% and Britain’s FTSE futures gaining 0.61%.

MSCI’s ex-Japan Asia index rose 1.43% after hitting a near three-month low on Thursday, as the Shanghai Composite Index gained 1.53%, snapping a three-day losing streak.

On Thursday, Chinese shares fell near a three-month low hit earlier in the month. The European Union joined Washington’s allies this week in imposing sanctions on officials in China’s Xinjiang region over allegations of human rights abuses, prompting retaliatory sanctions from Beijing.

“All the sanctions so far have been largely symbolic and should have little economic impact. But the Sino-U.S. confrontation is affecting market sentiment. It could take some time for them to come to any compromise,” said Yasutada Suzuki, head of emerging market investment at Sumitomo Mitsui Bank.

Japan’s Nikkei rose 1.47% after Wall Street shares staged a rally, driven by cheap, cyclical stocks that have been battered by the pandemic.

The Dow Jones Industrial Average rose 0.62% and the S&P 500 gained 0.52% while the Nasdaq Composite added just 0.12%.

“It’s month-end, quarter-end and for Japanese players, financial year-end, so we are seeing random flows from all kinds of players,” said Masanari Takada, cross asset strategist at Nomura Securities.

“But on the whole, those who were leading reflation trade based on their positive view on the Chinese economy are now closing their positions while those who didn’t get to ride on that wave are looking to see whether they should buy on dips.”

While markets were being driven more by various end-of-quarter trades than news flow, analysts noted overnight headlines were mostly supportive for stocks.

U.S. Labor Department data showed claims for unemployment benefits dropped to a one-year low last week, a sign that the U.S. economy is on the verge of stronger growth as the public health situation improves.

In his first formal news conference, U.S. President Joe Biden said that he would double his administration’s vaccination rollout plan after reaching the previous goal of 100 million shots 42 days ahead of schedule.

But while improvement in the U.S. health crisis has underpinned risk appetite globally, investors are increasingly alarmed by a divergence in health conditions.

“Vaccination in continental Europe is falling behind the schedule. Relative to the U.S., economic reopenings will likely be delayed as some countries are forced to impose lockdowns,” said Soichiro Matsumoto, chief investment officer, Japan, at Credit Suisse’s private banking unit in Tokyo.

That put pressure on the euro, which licked its wounds at $1.1782 after falling as low as $1.1762 overnight, its lowest levels since November.

The dollar also rose to 109.21 yen, within a striking distance from last week’s nine-month high of 109.365 yen.

The index of the U.S. currency stood near its highest level since mid-November, having gained 2.0% so far this month.

Oil prices rebounded a tad from a 4% drop on Thursday, though they are on course for their third straight week of losses on worries about a further reduction in demand. [O/R]

In addition to Europe, major developing economies such as Brazil and India are also struggling with a resurgence in COVID-19 cases.

The market still drew some support from concerns about supply disruption as a stranded container ship in the Suez Canal may block the vital shipping lane for weeks.

U.S. crude was last up 1.33% at $59.35 per barrel and Brent was at $62.62, up 1.08%.

Additional reporting by Katanga Johnson in Washington; editing by Richard Pullin, Ana Nicolaci da Costa and Lincoln Feast.

Read original article here

J&J vaccine adds to COVID-19 armoury, includes South African variant

(Reuters) – Johnson & Johnson said on Friday that its single-dose vaccine was 66% effective in preventing COVID-19 in a large global trial against multiple variants, giving health officials another weapon to tackle the pandemic.

In the trial of nearly 44,000 volunteers, the level of protection against moderate and severe COVID-19 varied from 72% in the United States, to 66% in Latin America and just 57% in South Africa, from where a worrying variant has spread.

The data showed that the vaccine’s effect on the South Africa variant was diminished compared to the unaltered virus, but infectious disease and public health experts said it can still help contain the virus spread and prevent deaths.

Midstage trial data from Novavax on Thursday also documented lower effectiveness in South Africa.

Rival shots from Pfizer/BioNTech and Moderna were both around 95% effective in preventing symptomatic illness in pivotal trials when given in two doses.

Those trials were conducted mainly in the United States and before the emergence of new variants. These mean that the world is racing against time and with limited supplies to vaccinate as many people as possible, and quickly, to prevent virus surges.

COVID-19 is rising in 37 countries and infections have surpassed 101 million globally.

Top U.S. infectious disease specialist Anthony Fauci said the world needs to vaccinate quickly to try to get ahead of these changes in the virus.

“It’s really a wake up call for us to be nimble and to be able to adjust as this virus will continue for certain to evolve,” Fauci said.

J&J’s main goal was the prevention of moderate to severe COVID-19, and the vaccine was 85% effective in stopping severe disease and preventing hospitalization across all geographies and against multiple variants 28 days after immunization.

That “will potentially protect hundreds of millions of people from serious and fatal outcomes of COVID-19,” Paul Stoffels, J&J’s chief scientific officer, said.

J&J shares were down 4% at $162.7 at 1700 GMT, with some Wall Street analysts saying its vaccine’s effectiveness was below those of rivals. Moderna’s stock gained 8% to $172.80.

SEEKING APPROVAL

J&J plans to seek emergency use authorization from the U.S. Food and Drug Administration next week and will soon follow up with the European Union and the rest of the world.

It has said it plans to deliver 1 billion doses of the vaccine, which it will make in the United States, Europe, South Africa and India, in 2021.

Public health officials are counting on it to increase much-needed supply and simplify immunization in the United States, which has a deal to buy 100 million doses of J&J’s vaccine and an option for an additional 200 million.

J&J said the vaccine would be ready immediately upon emergency approval, but Stoffels declined to say how many doses.

“The key is not only overall efficacy but specifically efficacy against severe disease, hospitalization, and death,” said Walid Gellad, a health policy associate professor at the University of Pittsburgh.

J&J’s vaccine uses a common cold virus to introduce coronavirus proteins into cells and trigger an immune response, whereas the Pfizer/BioNTech and Moderna vaccines employ a new technology called messenger RNA.

Unlike these vaccines, J&J’s does not require a second shot weeks after the first or need to be kept frozen, making it a strong candidate for use in parts of the world where transportation and cold storage present problems.

“Most countries are still desperate to get their hands on doses, regardless of whether or not the vaccine is considered highly effective. Moderately effective will do just fine for now,” Michael Breen, Director of Infectious Diseases and Ophthalmology at research firm GlobalData, said.

‘OVERWHELMED’

Several studies have emerged this month showing that a South African variant has mutated in areas of the virus that are key targets of vaccines, reducing their efficacy.

“What we are learning is there is different efficacy in different parts of the world,” Stoffels told Reuters.

In a sub-study of 6,000 volunteers in South Africa, Stoffels said, the J&J vaccine was 89% effective at preventing severe disease. In the South Africa portion of the trial, 95% of cases were infections with the South African variant.

“I am overwhelmed by the fact that this vaccine protected against severe disease even in South Africa,” said Glenda Gray, the joint lead investigator of the South African vaccine trial.

In the J&J trial, which was conducted in eight countries, 44% of participants were from the United States, 41% from Central and South America and 15% from South Africa. Just over a third of the volunteers were over 60.

Reporting by Julie Steenhuysen; Additional reporting by Manas Mishra, Dania Nadeem and Manojna Maddipatla in Bengalaru, Rebecca Spalding and Michael Erman in New York and Promit Mukherjee in Johannesburg; Writing by Alexander Smith; Editing by Peter Henderson, Edwina Gibbs, Keith Weir and Caroline Humer

Read original article here